South Korean pharmaceutical firm Celltrion announced positive results from a pre-clinical study of a new antiviral treatment for COVID-19 on Monday, reporting a 100-fold reduction in viral load of the disease in animal testing. The Incheon-based company said it anticipates starting its first clinical trials on humans in July, according to a news release issued Monday. Celltrion, which conducted the study in collaboration with South Korea's Chungbuk National University College ...